These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 22955920)

  • 1. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Tasian SK; Teachey DT; Li Y; Shen F; Harvey RC; Chen IM; Ryan T; Vincent TL; Willman CL; Perl AE; Hunger SP; Loh ML; Carroll M; Grupp SA
    Blood; 2017 Jan; 129(2):177-187. PubMed ID: 27777238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
    Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
    Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.
    Francis OL; Milford TA; Martinez SR; Baez I; Coats JS; Mayagoitia K; Concepcion KR; Ginelli E; Beldiman C; Benitez A; Weldon AJ; Arogyaswamy K; Shiraz P; Fisher R; Morris CL; Zhang XB; Filippov V; Van Handel B; Ge Z; Song C; Dovat S; Su RJ; Payne KJ
    Haematologica; 2016 Apr; 101(4):417-26. PubMed ID: 26611474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
    Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
    N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
    Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
    Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
    Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
    Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
    Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
    Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
    Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
    J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
    Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
    Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
    Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
    Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.
    Loh ML; Zhang J; Harvey RC; Roberts K; Payne-Turner D; Kang H; Wu G; Chen X; Becksfort J; Edmonson M; Buetow KH; Carroll WL; Chen IM; Wood B; Borowitz MJ; Devidas M; Gerhard DS; Bowman P; Larsen E; Winick N; Raetz E; Smith M; Downing JR; Willman CL; Mullighan CG; Hunger SP
    Blood; 2013 Jan; 121(3):485-8. PubMed ID: 23212523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
    Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.
    Cheng Y; Chikwava K; Wu C; Zhang H; Bhagat A; Pei D; Choi JK; Tong W
    J Clin Invest; 2016 Apr; 126(4):1267-81. PubMed ID: 26974155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis.
    Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE
    Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The JAK1/JAK2- inhibitor ruxolitinib inhibits mast cell degranulation and cytokine release.
    Hermans MAW; Schrijver B; van Holten-Neelen CCPA; Gerth van Wijk R; van Hagen PM; van Daele PLA; Dik WA
    Clin Exp Allergy; 2018 Nov; 48(11):1412-1420. PubMed ID: 29939445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
    Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
    PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.